3rd Quarter - Report

IGM BIOSCIENCES, INC. for IGM BIOSCIENCES, INC.

Period 3rd Quarter 2023 Filed Oct 20, 2023 Signed by Andrew Womack

Official filing
Firm
IGM BIOSCIENCES, INC.
Client
IGM BIOSCIENCES, INC.
Income
—
Expenses
$230,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

COVID Supplemental Appropriation S.2076/H.R.3932 - PASTEUR Act of 2021 S.3799 - PREVENT Pandemics Act Issues related to the development of an antibody therapy for COVID-19 Issues related to antimicrobial resistance (AMR) and drug development Issues related to supply chain and biopharmaceutical manufacturing FY2024 Defense Appropriations Issues related to the reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) National Biodefense Strategy and Implementation Plan H.R.3746 Fiscal Responsibility Act of 2023 H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act

LobbyistCovered position, as disclosed
ANDREW WESLEY WOMACK —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP)

Bills named: H.R. 3746 (118th), S. 3799 (118th), H.R. 3932 (118th), H.R. 4421 (118th), S. 2076 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.